KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Times Interest Earned: 2010-2020

Historic Times Interest Earned for Nektar Therapeutics (NKTR) over the last 10 years, with Jun 2020 value amounting to -$120.11.

  • Nektar Therapeutics' Times Interest Earned fell 466.17% to -$120.11 in Q2 2020 from the same period last year, while for Jun 2020 it was -$23.71, marking a year-over-year decrease of 17.35%. This contributed to the annual value of -$62.05 for FY2020, which is 200.50% down from last year.
  • Per Nektar Therapeutics' latest filing, its Times Interest Earned stood at -$120.11 for Q2 2020, which was down 457.61% from -$21.54 recorded in Q1 2020.
  • In the past 5 years, Nektar Therapeutics' Times Interest Earned registered a high of $180.80 during Q2 2018, and its lowest value of -$120.11 during Q2 2020.
  • Over the past 3 years, Nektar Therapeutics' median Times Interest Earned value was -$19.36 (recorded in 2018), while the average stood at -$9.64.
  • Per our database at Business Quant, Nektar Therapeutics' Times Interest Earned slumped by 5,977.31% in 2016 and then surged by 2,066.60% in 2018.
  • Over the past 5 years, Nektar Therapeutics' Times Interest Earned (Quarterly) stood at -$5.79 in 2016, then grew by 26.33% to -$4.27 in 2017, then tumbled by 334.10% to -$18.52 in 2018, then fell by 9.05% to -$20.20 in 2019, then tumbled by 466.17% to -$120.11 in 2020.
  • Its Times Interest Earned stands at -$120.11 for Q2 2020, versus -$21.54 for Q1 2020 and -$20.20 for Q4 2019.